Thiogenesis Therapeutics Plans Phase 3 Trial for Next-Generation Cystinosis Treatment TTI-0102
核心洞察
Thiogenesis Therapeutics (搜索) announced plans to initiate a Phase 3 pivotal trial of TTI-0102 for nephropathic cystinosis (搜索), with an IND application expected in early 2026.
TTI-0102 is designed as a once-daily oral prodrug to address limitations of current cysteamine therapies, which require multiple daily doses and cause significant side effects.
The global cystinosis population exceeds 2,000 patients worldwide, representing a market opportunity of over $300 million for improved treatments.
Thiogenesis Therapeutics (搜索) announced plans to initiate a Phase 3 pivotal clinical trial of its lead compound TTI-0102 for the treatment of nephropathic cystinosis (搜索), an inherited lysosomal storage disorder requiring lifelong cystine-depleting therapy. The San Diego-based clinical-stage biotechnology company plans to submit an Investigational New Drug (IND) application in early 2026.
Addressing Unmet Medical Need in Rare Disease
Nephropathic cystinosis (搜索) is a rare, autosomal recessive lysosomal storage disorder caused by mutations in CTNS (搜索), leading to toxic intracellular cystine accumulation and progressive multi-organ damage. Without disease-modifying therapy, patients develop renal Fanconi syndrome (搜索), growth failure, and progression to end-stage renal disease.
The global cystinosis population exceeds 2,000 patients worldwide, representing a market opportunity of over $300 million. Currently, there are two approved drugs for cystinosis: immediate release cysteamine (Cystagon®) and delayed-release cysteamine (Procysbi®). Both require multiple daily dosings and have significant side effects, with tolerability challenges frequently leading to suboptimal adherence.
Next-Generation Prodrug Design
TTI-0102 is a next-generation cysteamine-based prodrug engineered to address longstanding limitations of current standard-of-care therapies including their short half-life, side effects and dosing frequency. The compound is a sulfur-based disulfide prodrug consisting of two cysteamine molecules and one molecule of pantothenic acid (Vitamin B5).
Following oral administration, metabolic activation delivers sustained cysteamine exposure with reduced peak-related toxicity, enabling once-daily dosing. TTI-0102 is designed to potentially offer:
- Once-daily oral dosing, enabled by controlled prodrug metabolism and extended exposure
- Reduced peak-related GI intolerance, a major limitation of current cysteamine products
- Improved tolerability across weight ranges, supported by results from the Company's MELAS Phase 2 program
- Dual mechanistic activity: cystine depletion and enhancement of intracellular antioxidant pathways (glutathione and taurine), consistent with cysteamine biology
Leveraging Clinical Experience and Regulatory Pathway
Despite being a New Chemical Entity (NCE), TTI-0102 is reduced and metabolized in the GI tract releasing cysteamine, the active ingredient in Cystagon® and Procysbi®. Therefore, the Phase 3 trial will be conducted under the FDA's 505(b)(2) regulatory pathway.
A key design advantage of the planned pivotal study is the incorporation of dosing insights from Thiogenesis' ongoing Phase 2 MELAS (搜索) trial, which demonstrated:
- Clear biomarker responses supporting thiol-mediated mitochondrial antioxidant activity
- Dose-dependent tolerability patterns, particularly in lighter-weight patients
- A fully characterized exposure-response profile, now informing cystinosis trial dosing strategies
These data enable Thiogenesis to initiate a cystinosis Phase 3 program with refined dosing regimens and enhanced biological rationale, reducing typical development risk.
Current Standard of Care Limitations
Delayed-release cysteamine remains the current standard-of-care but is associated with twice-a-day dosing requirements and common adverse events including nausea, vomiting, diarrhea, abdominal pain, halitosis, and dysgeusia. Additionally, fibrosing colonopathy (搜索), a rare but serious adverse event identified in multiple post-marketing case reports, prompted FDA labeling changes in 2022.
"We understand the underlying mechanism of cystinosis at a deep biochemical level, cystine accumulation, oxidative stress, and the burden of lifelong thiol therapy," said Dr. Patrice Rioux, Chief Executive Officer, Thiogenesis Therapeutics (搜索). "TTI-0102 was engineered specifically to overcome the limitations of existing cysteamine formulations. By enabling the potential for once-daily or reduced dosing with a far better tolerability profile, we believe TTI-0102 represents the next-generation therapy that patients and families that would significantly increase their quality of life."
Broader Development Pipeline
TTI-0102 is currently in clinical development for multiple indications beyond cystinosis, including MELAS (搜索), Leigh syndrome (搜索), and pediatric MASH (搜索). The company's leadership and clinical team previously played pivotal roles in successfully advancing delayed-release cysteamine through clinical development and commercialization, providing unique insight into optimal trial design and cysteamine pharmacology.